Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT) and Quidel Corp (QDEL)


Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on PTC Therapeutics (NASDAQ:PTCT) and Quidel Corp (NASDAQ:QDEL).

PTC Therapeutics (PTCT)

Barclays analyst Gena Wang maintained a Hold rating on PTC Therapeutics today and set a price target of $43. The company’s shares closed yesterday at $38.29.

According to TipRanks.com, Wang is a 5-star analyst with an average return of 24.5% and a 53.0% success rate. Wang covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Sarepta Therapeutics, and Mirati Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PTC Therapeutics with a $46 average price target.

See today’s analyst top recommended stocks >>

Quidel Corp (QDEL)

Barclays analyst Jack Meehan maintained a Buy rating on Quidel Corp today and set a price target of $80. The company’s shares closed yesterday at $71.69, close to its 52-week high of $73.36.

According to TipRanks.com, Meehan is a 4-star analyst with an average return of 10.3% and a 65.3% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Genomic Health, Thermo Fisher, and Icon plc.

Quidel Corp has an analyst consensus of Strong Buy, with a price target consensus of $76.33, a 6.5% upside from current levels. In a report released yesterday, Piper Jaffray also reiterated a Buy rating on the stock with a $74 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts